Stay updated with breaking news from Cambridge Based Biogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Blue Cross Blue Shield of Massachusetts initially balked at covering the treatment — which costs $26,500 per year per patient — because it considered Leqembi “investigational,” or experimental.
The pill, called Zurzuvae, has generated lots of interest among psychiatrists, OB-GYNs, and primary care physicians, the executive said.
As more than 8,000 biotech executives, investors and analysts converge this week for the 42nd Annual J.P. Morgan Healthcare Conference — the largest biotech business meeting of the year — industry leaders see reasons to be optimistic.
Vertex wants to interrupt pain signals before they reach the brain, and because its non-opioid drug would bypass the central nervous system, it would provide pain relief without the risk of addiction.
Signs of cognitive decline and memory loss may not show up for 10 to 20 years after the formation of deposits of amyloid and other toxic proteins in the brain, experts say.